1 5719 79 SIRTUINS IN NEURODEGENERATIVE DISEASES: AN UPDATE ON POTENTIAL MECHANISMS. SILENT INFORMATION REGULATOR 2 PROTEINS (SIRTUINS OR SIRTS) ARE A GROUP OF DEACETYLASES (OR DEACYLASES) WHOSE ACTIVITIES ARE DEPENDENT ON AND REGULATED BY NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD(+)). COMPELLING EVIDENCE SUPPORTS THAT SIRTUINS PLAY MAJOR ROLES IN MANY ASPECTS OF PHYSIOLOGY, ESPECIALLY IN PATHWAYS RELATED TO AGING - THE PREDOMINANT AND UNIFYING RISK FACTOR FOR NEURODEGENERATIVE DISEASES. IN THIS REVIEW, WE HIGHLIGHT THE MOLECULAR MECHANISMS UNDERLYING THE PROTECTIVE EFFECTS OF SIRTUINS IN NEURODEGENERATIVE DISEASES, FOCUSING ON PROTEIN HOMEOSTASIS, NEURAL PLASTICITY, MITOCHONDRIAL FUNCTION, AND SUSTAINED CHRONIC INFLAMMATION. WE WILL ALSO EXAMINE THE POTENTIAL AND CHALLENGES OF TARGETING SIRTUIN PATHWAYS TO BLOCK THESE PATHOGENIC PATHWAYS. 2013 2 5707 27 SIRT1 AS A THERAPEUTIC TARGET IN DIABETIC COMPLICATIONS. BACKGROUND: SIRTUIN1 IS AN EPIGENETIC ENZYME INVOLVED IN HISTONE AND NONHISTONE PROTEIN DEACETYLATION. IT ACTS PRIMARILY AS A METABOLIC SENSOR, WHICH RESPONSES TO CHANGING ENERGY STATUS BY DEACETYLATING CRUCIAL TRANSCRIPTION FACTORS AND COFACTORS. IN THIS WAY, SIRTUIN1 REGULATES MITOCHONDRIAL FUNCTION AND BIOGENESIS, OXIDATIVE STRESS, INFLAMMATION, APOPTOSIS AND CELLULAR SENESCENCE. DISTURBANCE OF ALL OF THESE PHENOMENA PROMOTES THE PATHOGENESIS OF DIABETIC COMPLICATIONS. THESE DISORDERS ARE INSEPARABLY CONNECTED WITH CHRONIC HYPERGLYCEMIA, WHICH POSSESSES A STRONG EPIGENETIC DETERMINANT. OBJECTIVE: TO SUMMARIZE THE CONTEMPORARY KNOWLEDGE REGARDING THE ROLE OF SIRTUIN1 IN THE DEVELOPMENT, PROGRESSION AND THERAPY OF DIABETIC COMPLICATIONS. METHODS: WE EXTENSIVELY SEARCHED LITERATURE DESCRIBING THE IMPORTANCE OF SIRTUIN1 IN PATHOPHYSIOLOGY AND TREATMENT OF ALL KINDS OF DIABETIC COMPLICATIONS TILL SEPTEMBER 2017. WE FOCUSED ON THE EXAMPLES OF SYNTHETIC AND NATURAL COMPOUNDS-MEDIATED SIRTUIN1 UPREGULATION ALONG WITH SIRTUIN1-ASSOCIATED EPIGENETICS. RESULTS: REDUCTION OF SIRTUIN1 IS IMPLICATED IN ENDOTHELIAL DYSFUNCTION AND METABOLIC MEMORY, UNDERLYING THE DEVELOPMENT OF MICRO- AND MACROVASCULAR COMPLICATIONS. DECLINED SIRTUIN1 ALSO PARTICIPATES IN DIABETIC TESTICULAR AND ERECTILE DYSFUNCTION. SIRTUIN1 IS ELEVATED BY NATURALLY OCCURRING ANTI-OXIDANT AND ANTI-INFLAMMATORY COMPOUNDS SUCH AS RESVERATROL, TRANS-DELTA-VINIFERIN, VITAMIN D AND MORE. SIMILARLY, SIRTUIN1 LEVEL INCREASES AFTER TREATMENT WITH STANDARD ANTIHYPERGLYCEMIC (METFORMIN, EXENATIDE, LIRAGLUTIDE), ANTIHYPERTENSIVE (SARTANS), LIPID-LOWERING (FIBRATES, STATINS) AND ANTICOAGULANT (FIDARESTAT) DRUGS. REGARDING EPIGENETICS, A NUMBER OF MIRNAS TRIGGER SIRTUIN1 DECREASE, WHICH FURTHER CONTRIBUTES TO HISTONE ACETYLATION OF SIRTUIN1-REGULATED AND RELEVANT FOR DIABETES GENES. CONCLUSION: EVIDENCE STRONGLY SUGGEST THAT SIRTUIN1 UPREGULATION MAY SERVE AS A POTENT THERAPEUTIC APPROACH AGAINST DEVELOPMENT AND PROGRESSION OF DIABETIC COMPLICATIONS. 2018 3 5721 23 SIRTUINS-NOVEL REGULATORS OF EPIGENETIC ALTERATIONS IN AIRWAY INFLAMMATION. HISTONE MODIFICATION IS AN IMPORTANT EPIGENETIC ALTERATION, AND HISTONE DEACETYLASES ARE INVOLVED IN THE OCCURRENCE AND DEVELOPMENT OF VARIOUS RESPIRATORY DISEASES. SIRTUINS (SIRTS) HAVE BEEN DEMONSTRATED TO PLAY AN IMPORTANT ROLE IN THE FORMATION AND PROGRESSION OF CHRONIC INFLAMMATORY DISEASES OF THE RESPIRATORY TRACT. SIRTS PARTICIPATE IN THE REGULATION OF OXIDATIVE STRESS AND INFLAMMATION AND ARE RELATED TO CELL STRUCTURE AND CELLULAR LOCALIZATION. THIS PAPER SUMMARIZES THE ROLES AND MECHANISMS OF SIRTS IN AIRWAY INFLAMMATION AND DESCRIBES THE LATEST RESEARCH ON SIRT MODULATORS, AIMING TO PROVIDE A THEORETICAL BASIS FOR THE STUDY OF POTENTIAL EPIGENETIC ALTERATION-INDUCING DRUG TARGETS. 2022 4 5720 30 SIRTUINS LINK INFLAMMATION AND METABOLISM. SIRTUINS (SIRT), FIRST DISCOVERED IN YEAST AS NAD+ DEPENDENT EPIGENETIC AND METABOLIC REGULATORS, HAVE COMPARABLE ACTIVITIES IN HUMAN PHYSIOLOGY AND DISEASE. MOUNTING EVIDENCE SUPPORTS THAT THE SEVEN-MEMBER MAMMALIAN SIRTUIN FAMILY (SIRT1-7) GUARD HOMEOSTASIS BY SENSING BIOENERGY NEEDS AND RESPONDING BY MAKING ALTERATIONS IN THE CELL NUTRIENTS. SIRTUINS PLAY A CRITICAL ROLE IN RESTORING HOMEOSTASIS DURING STRESS RESPONSES. INFLAMMATION IS DESIGNED TO "DEFEND AND MEND" AGAINST THE INVADING ORGANISMS. EMERGING EVIDENCE SUPPORTS THAT METABOLISM AND BIOENERGY REPROGRAMMING DIRECT THE SEQUENTIAL COURSE OF INFLAMMATION; FAILURE OF HOMEOSTASIS RETRIEVAL RESULTS IN MANY CHRONIC AND ACUTE INFLAMMATORY DISEASES. ANABOLIC GLYCOLYSIS QUICKLY INDUCED (COMPARED TO OXIDATIVE PHOSPHORYLATION) FOR ROS AND ATP GENERATION IS NEEDED FOR IMMUNE ACTIVATION TO "DEFEND" AGAINST INVADING MICROORGANISMS. LIPOLYSIS/FATTY ACID OXIDATION, ESSENTIAL FOR CELLULAR PROTECTION/HIBERNATION AND CELL SURVIVAL IN ORDER TO "MEND," LEADS TO IMMUNE REPRESSION. ACUTE/CHRONIC INFLAMMATIONS ARE LINKED TO ALTERED GLYCOLYSIS AND FATTY ACID OXIDATION, AT LEAST IN PART, BY NAD+ DEPENDENT FUNCTION OF SIRTUINS. THERAPEUTICALLY TARGETING SIRTUINS MAY PROVIDE A NEW CLASS OF INFLAMMATION AND IMMUNE REGULATORS. THIS REVIEW DISCUSSES HOW SIRTUINS INTEGRATE METABOLISM, BIOENERGETICS, AND IMMUNITY DURING INFLAMMATION AND HOW SIRTUIN-DIRECTED TREATMENT IMPROVES OUTCOME IN CHRONIC INFLAMMATORY DISEASES AND IN THE EXTREME STRESS RESPONSE OF SEPSIS. 2016 5 5322 18 PULMONARY DISEASES AND AGEING. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND IDIOPATHIC PULMONARY FIBROSIS ARE REGARDED AS A DISEASES OF ACCELERATED LUNG AGEING AND SHOW ALL OF THE HALLMARKS OF AGEING, INCLUDING TELOMERE SHORTENING, CELLULAR SENESCENCE, ACTIVATION OF PI3 KINASE-MTOR SIGNALING, IMPAIRED AUTOPHAGY, MITOCHONDRIAL DYSFUNCTION, STEM CELL EXHAUSTION, EPIGENETIC CHANGES, ABNORMAL MICRORNA PROFILES, IMMUNOSENESCENCE AND A LOW GRADE CHRONIC INFLAMMATION DUE TO SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP). MANY OF THESE AGEING MECHANISMS ARE DRIVEN BY EXOGENOUS AND ENDOGENOUS OXIDATIVE STRESS. THERE IS ALSO A REDUCTION IN ANTI-AGEING MOLECULES, SUCH AS SIRTUINS AND KLOTHO, WHICH FURTHER ACCELERATE THE AGEING PROCESS. UNDERSTANDING THESE MOLECULAR MECHANISMS HAS IDENTIFIED SEVERAL NOVEL THERAPEUTIC TARGETS AND SEVERAL DRUGS AND DIETARY INTERVENTIONS ARE NOW IN DEVELOPMENT TO TREAT CHRONIC LUNG DISEASE. 2019 6 4772 28 NUCLEAR SIRTUINS AND INFLAMMATORY SIGNALING PATHWAYS. THE REGULATION OF CHRONIC INFLAMMATION HAS RECEIVED CONSIDERABLE RESEARCH ATTENTION IN RECENT YEARS BECAUSE OF ITS CONTRIBUTION TO THE PATHOGENESIS OF CHRONIC DISEASES SUCH AS ARTHRITIS, DIABETES, METABOLIC SYNDROME AND OBESITY. THUS, STRATEGIES THAT INHIBIT THE INFLAMMATORY STATE MAY BE BENEFICIAL IN IMPROVING THE PATHOPHYSIOLOGY OF SEVERAL INFLAMMATION-RELATED DISORDERS. SIRTUINS ARE A FAMILY OF HISTONE DEACETYLASES THAT CONTAIN SEVEN ENZYMATIC ACTIVITIES IN MAMMALS (SIRT1-SIRT7) AND FUNCTION TO SUPPRESS GENE TRANSCRIPTION BY EPIGENETIC MECHANISMS. NUCLEAR SIRTUINS (SIRT 1, 2, 6 AND 7) IN PARTICULAR MAY PLAY AN IMPORTANT ROLE IN THE REGULATION OF INFLAMMATORY RESPONSES. IN THE PRESENT REVIEW, WE ASSESSED THE ROLES OF NUCLEAR SIRTUINS IN INFLAMMATORY REACTIONS: SIRT1 HAS BEEN SHOWN TO SUPPRESS NF-KAPPAB ACTIVITY, THE MASTER REGULATOR OF CELLULAR INFLAMMATORY RESPONSE, DECREASE COX-2 AND INOS PRODUCTION, AND INCREASE ANTIOXIDANT GENE EXPRESSION THAT SUPPRESSED INFLAMMATION. SIRT2 ACTIVITY INCLUDED THE DEACETYLATION OF P65 SUBUNIT OF NF-KAPPABETA AND RIP-1, WHILE SIRT6 HAS BEEN SHOWN TO INTERACT WITH P65/RELA BOUND TO THE NF-KAPPABETA PROMOTER REGION AND REPRESS TRANSCRIPTIONAL ACTIVITY. FURTHERMORE, RECENT STUDIES HAVE SHOWN THAT THE ABSENCE OF SIRT7 PRODUCED AN INCREASE IN INFLAMMATION, ILLUSTRATING THAT SIRT7 ALSO FUNCTIONED TO DECREASE INFLAMMATION. GIVEN THEIR SIGNIFICANT ROLES IN THE REGULATION OF CHRONIC INFLAMMATION, NUCLEAR SIRTUINS REPRESENT POTENTIAL THERAPEUTIC TARGETS IN THE CONTROL OF CHRONIC INFLAMMATORY DISEASES. 2017 7 5629 22 SENESCENCE IN COPD AND ITS COMORBIDITIES. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS REGARDED AS A DISEASE OF ACCELERATED LUNG AGING. THIS AFFLICTION SHOWS ALL OF THE HALLMARKS OF AGING, INCLUDING TELOMERE SHORTENING, CELLULAR SENESCENCE, ACTIVATION OF PI3 KINASE-MTOR SIGNALING, IMPAIRED AUTOPHAGY, MITOCHONDRIAL DYSFUNCTION, STEM CELL EXHAUSTION, EPIGENETIC CHANGES, ABNORMAL MICRORNA PROFILES, IMMUNOSENESCENCE, AND A LOW-GRADE CHRONIC INFLAMMATION (INFLAMMAGING). MANY OF THESE PATHWAYS ARE DRIVEN BY CHRONIC EXOGENOUS AND ENDOGENOUS OXIDATIVE STRESS. THERE IS ALSO A REDUCTION IN ANTIAGING MOLECULES, SUCH AS SIRTUINS AND KLOTHO, WHICH FURTHER ACCELERATE THE AGING PROCESS. COPD IS ASSOCIATED WITH SEVERAL COMORBIDITIES (MULTIMORBIDITY), SUCH AS CARDIOVASCULAR AND METABOLIC DISEASES, THAT SHARE THE SAME PATHWAYS OF ACCELERATED AGING. UNDERSTANDING THESE MECHANISMS HAS HELPED IDENTIFY SEVERAL NOVEL THERAPEUTIC TARGETS, AND SEVERAL DRUGS AND DIETARY INTERVENTIONS ARE NOW IN DEVELOPMENT TO TREAT MULTIMORBIDITY. 2017 8 5409 28 REGULATION OF ACETYLATION STATES BY NUTRIENTS IN THE INHIBITION OF VASCULAR INFLAMMATION AND ATHEROSCLEROSIS. ATHEROSCLEROSIS (AS) IS A CHRONIC METABOLIC DISORDER AND PRIMARY CAUSE OF CARDIOVASCULAR DISEASES, RESULTING IN SUBSTANTIAL MORBIDITY AND MORTALITY WORLDWIDE. INITIATED BY ENDOTHELIAL CELL STIMULATION, AS IS CHARACTERIZED BY ARTERIAL INFLAMMATION, LIPID DEPOSITION, FOAM CELL FORMATION, AND PLAQUE DEVELOPMENT. NUTRIENTS SUCH AS CAROTENOIDS, POLYPHENOLS, AND VITAMINS CAN PREVENT THE ATHEROSCLEROTIC PROCESS BY MODULATING INFLAMMATION AND METABOLIC DISORDERS THROUGH THE REGULATION OF GENE ACETYLATION STATES MEDIATED WITH HISTONE DEACETYLASES (HDACS). NUTRIENTS CAN REGULATE AS-RELATED EPIGENETIC STATES VIA SIRTUINS (SIRTS) ACTIVATION, SPECIFICALLY SIRT1 AND SIRT3. NUTRIENT-DRIVEN ALTERATIONS IN THE REDOX STATE AND GENE MODULATION IN AS PROGRESSION ARE LINKED TO THEIR PROTEIN DEACETYLATING, ANTI-INFLAMMATORY, AND ANTIOXIDANT PROPERTIES. NUTRIENTS CAN ALSO INHIBIT ADVANCED OXIDATION PROTEIN PRODUCT FORMATION, REDUCING ARTERIAL INTIMA-MEDIA THICKNESS EPIGENETICALLY. NONETHELESS, KNOWLEDGE GAPS REMAIN WHEN IT COMES TO UNDERSTANDING EFFECTIVE AS PREVENTION THROUGH EPIGENETIC REGULATION BY NUTRIENTS. THIS WORK REVIEWS AND CONFIRMS THE UNDERLYING MECHANISMS BY WHICH NUTRIENTS PREVENT ARTERIAL INFLAMMATION AND AS, FOCUSING ON THE EPIGENETIC PATHWAYS THAT MODIFY HISTONES AND NON-HISTONE PROTEINS BY REGULATING REDOX AND ACETYLATION STATES THROUGH HDACS SUCH AS SIRTS. THESE FINDINGS MAY SERVE AS A FOUNDATION FOR DEVELOPING POTENTIAL THERAPEUTIC AGENTS TO PREVENT AS AND CARDIOVASCULAR DISEASES BY EMPLOYING NUTRIENTS BASED ON EPIGENETIC REGULATION. 2023 9 4585 32 NAD(+) AND VASCULAR DYSFUNCTION: FROM MECHANISMS TO THERAPEUTIC OPPORTUNITIES. NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD(+)) IS AN ESSENTIAL AND PLEIOTROPIC COENZYME INVOLVED NOT ONLY IN CELLULAR ENERGY METABOLISM, BUT ALSO IN CELL SIGNALING, EPIGENETIC REGULATION, AND POST-TRANSLATIONAL PROTEIN MODIFICATIONS. VASCULAR DISEASE RISK FACTORS ARE ASSOCIATED WITH ABERRANT NAD(+) METABOLISM. CONVERSELY, THE THERAPEUTIC INCREASE OF NAD(+) LEVELS THROUGH THE ADMINISTRATION OF NAD(+) PRECURSORS OR INHIBITORS OF NAD(+)-CONSUMING ENZYMES REDUCES CHRONIC LOW-GRADE INFLAMMATION, REACTIVATES AUTOPHAGY AND MITOCHONDRIAL BIOGENESIS, AND ENHANCES OXIDATIVE METABOLISM IN VASCULAR CELLS OF HUMANS AND RODENTS WITH VASCULAR PATHOLOGIES. AS SUCH, NAD(+) HAS EMERGED AS A POTENTIAL TARGET FOR COMBATTING AGE-RELATED CARDIOVASCULAR AND CEREBROVASCULAR DISORDERS. THIS REVIEW DISCUSSES NAD(+)-REGULATED MECHANISMS CRITICAL FOR VASCULAR HEALTH AND SUMMARIZES NEW ADVANCES IN NAD(+) RESEARCH DIRECTLY RELATED TO VASCULAR AGING AND DISEASE, INCLUDING HYPERTENSION, ATHEROSCLEROSIS, CORONARY ARTERY DISEASE, AND AORTIC ANEURYSMS. FINALLY, WE ENUMERATE CHALLENGES AND OPPORTUNITIES FOR NAD(+) REPLETION THERAPY WHILE ANTICIPATING THE FUTURE OF THIS EXCITING RESEARCH FIELD, WHICH WILL HAVE A MAJOR IMPACT ON VASCULAR MEDICINE. 2022 10 4902 24 OXIDATIVE-STRESS-INDUCED EPIGENETIC CHANGES IN CHRONIC DIABETIC COMPLICATIONS. OXIDATIVE STRESS PLAYS AN IMPORTANT ROLE IN THE DEVELOPMENT AND PROGRESSION OF CHRONIC DIABETIC COMPLICATIONS. DIABETES CAUSES MITOCHONDRIAL SUPEROXIDE OVERPRODUCTION IN THE ENDOTHELIAL CELLS OF BOTH LARGE AND SMALL VESSELS. THIS INCREASED SUPEROXIDE PRODUCTION CAUSES THE ACTIVATION OF SEVERAL SIGNAL PATHWAYS INVOLVED IN THE PATHOGENESIS OF CHRONIC COMPLICATIONS. IN PARTICULAR, ENDOTHELIAL CELLS ARE MAJOR TARGETS OF GLUCOSE-INDUCED OXIDATIVE DAMAGE IN THE TARGET ORGANS. OXIDATIVE STRESS ACTIVATES CELLULAR SIGNALING PATHWAYS AND TRANSCRIPTION FACTORS IN ENDOTHELIAL CELLS INCLUDING PROTEIN KINASE C (PKC), C-JUN-N-TERMINAL KINASE (JNK), P38 MITOGEN-ACTIVATED PROTEIN KINASE (MAPK), FORKHEAD BOX O (FOXO), AND NUCLEAR FACTOR KAPPA-B (NF-KAPPAB). OXIDATIVE STRESS ALSO CAUSES DNA DAMAGE AND ACTIVATES DNA NUCLEOTIDE EXCISION REPAIR ENZYMES INCLUDING THE EXCISION REPAIR CROSS COMPLIMENTING 1(ERCC1), ERCC4, AND POLY(ADP-RIBOSE) POLYMERASE (PARP). AUGMENTED PRODUCTION OF HISTONE ACETYLTRANSFERASE P300, AND ALTERATIONS OF HISTONE DEACETYLASES, INCLUDING CLASS III DEACETYLASES SIRTUINS, ARE ALSO INVOLVED IN THIS PROCESS. RECENT RESEARCH HAS FOUND THAT SMALL NONCODING RNAS, LIKE MICRORNA, ARE A NEW KIND OF REGULATOR ASSOCIATED WITH CHRONIC DIABETIC COMPLICATIONS. THERE ARE EXTENSIVE AND COMPLICATED INTERACTIONS AND AMONG THESE MOLECULES. THE PURPOSE OF THIS REVIEW IS TO DEMONSTRATE THE ROLE OF OXIDATIVE STRESS IN THE DEVELOPMENT OF DIABETIC COMPLICATIONS IN RELATION TO EPIGENETIC CHANGES SUCH AS ACETYLATION AND MICRORNA ALTERATIONS. 2013 11 4031 31 LYSINE DEACETYLASE (KDAC) REGULATORY PATHWAYS: AN ALTERNATIVE APPROACH TO SELECTIVE MODULATION. PROTEIN LYSINE DEACETYLASES (KDACS), INCLUDING THE CLASSIC ZN(2+) -DEPENDENT HISTONE DEACETYLASES (HDACS) AND THE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD(+) )-REQUIRING SIRTUINS, ARE ENZYMES THAT PLAY CRITICAL ROLES IN NUMEROUS BIOLOGICAL PROCESSES, PARTICULARLY THE EPIGENETIC REGULATION OF GLOBAL GENE EXPRESSION PROGRAMS IN RESPONSE TO INTERNAL AND EXTERNAL CUES. DYSREGULATION OF KDACS IS CHARACTERISTIC OF SEVERAL HUMAN DISEASES, INCLUDING CHRONIC METABOLIC, NEURODEGENERATIVE, AND CARDIOVASCULAR DISEASES AND MANY CANCERS. THIS HAS LED TO THE DEVELOPMENT OF KDAC MODULATORS, TWO OF WHICH (HDAC INHIBITORS VORINOSTAT AND ROMIDEPSIN) HAVE BEEN APPROVED FOR THE TREATMENT OF CUTANEOUS T CELL LYMPHOMA. BY THEIR NATURE, EXISTING KDAC MODULATORS ARE RELATIVELY NONSPECIFIC, LEADING TO PAN-KDAC CHANGES AND UNDESIRED SIDE EFFECTS. GIVEN THAT KDACS ARE REGULATED AT MANY LEVELS, INCLUDING TRANSCRIPTIONAL, POST-TRANSLATIONAL, SUBCELLULAR LOCALIZATION, AND THROUGH THEIR COMPLEXATION WITH OTHER PROTEINS, IT SHOULD BE POSSIBLE TO AFFECT SPECIFIC KDAC ACTIVITY THROUGH MANIPULATION OF ENDOGENOUS SIGNALING PATHWAYS. IN THIS MINIREVIEW, WE DISCUSS OUR PRESENT KNOWLEDGE OF THE CELLULAR CONTROLS OF KDAC ACTIVITY AND EXAMPLES OF THEIR PHARMACOLOGIC REGULATION. 2014 12 870 22 CHRONIC ALCOHOL BINGING INJURES THE LIVER AND OTHER ORGANS BY REDUCING NAD(+) LEVELS REQUIRED FOR SIRTUIN'S DEACETYLASE ACTIVITY. NAD(+) LEVELS ARE MARKEDLY REDUCED WHEN BLOOD ALCOHOL LEVELS ARE HIGH DURING BINGE DRINKING. THIS CAUSES LIVER INJURY TO OCCUR BECAUSE THE ENZYMES THAT REQUIRE NAD(+) AS A COFACTOR SUCH AS THE SIRTUIN DE-ACETYLASES CANNOT DE-ACETYLATE ACETYLATED PROTEINS SUCH AS ACETYLATED HISTONES. THIS PREVENTS THE EPIGENETIC CHANGES THAT REGULATE METABOLIC PROCESSES AND WHICH PREVENT ORGAN INJURY SUCH AS FATTY LIVER IN RESPONSE TO ALCOHOL ABUSE. HYPER ACETYLATION OF NUMEROUS REGULATORY PROTEINS DEVELOPS. SYSTEMIC MULTI-ORGAN INJURY OCCURS WHEN NAD(+) IS REDUCED. FOR INSTANCE THE CIRCADIAN CLOCK IS ALTERED IF NAD(+) IS NOT AVAILABLE. CELL CYCLE ARREST OCCURS DUE TO UP REGULATION OF CELL CYCLE INHIBITORS LEADING TO DNA DAMAGE, MUTATIONS, APOPTOSIS AND TUMORIGENESIS. NAD(+) IS LINKED TO AGING IN THE REGULATION OF TELOMERE STABILITY. NAD(+) IS REQUIRED FOR MITOCHONDRIAL RENEWAL. ALCOHOL DEHYDROGENASE IS PRESENT IN EVERY VISCERAL ORGAN IN THE BODY SO THAT THERE IS A SYSTEMIC REDUCTION OF NAD(+) LEVELS IN ALL OF THESE ORGANS DURING BINGE DRINKING. 2016 13 1251 24 CURRENT PERSPECTIVES ON ROLE OF CHROMATIN MODIFICATIONS AND DEACETYLASES IN LUNG INFLAMMATION IN COPD. CHROMATIN MODIFICATIONS AND EPIGENETIC REGULATION ARE CRITICAL FOR SUSTAINED AND ABNORMAL INFLAMMATORY RESPONSE SEEN IN LUNGS OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BECAUSE THE ACTIVITIES OF ENZYMES THAT REGULATE THESE EPIGENETIC MODIFICATIONS ARE ALTERED IN RESPONSE TO CIGARETTE SMOKE. CIGARETTE SMOKE INDUCES CHROMATIN MODIFICATIONS AND EPIGENETIC CHANGES BY CAUSING POST-TRANSLATIONAL MODIFICATIONS OF HISTONE ACETYLTRANSFERASES, AND HISTONE/NON-HISTONE DEACETYLASES (HDACS), SUCH AS HDAC2 AND SIRTUIN 1 (SIRT1), WHICH LEADS TO CHROMATIN REMODELING. IN THIS REVIEW, WE DISCUSSED THE CURRENT KNOWLEDGE ON CIGARETTE SMOKE/OXIDANTS-INDUCED POST-TRANSLATIONAL MODIFICATIONS OF DEACETYLASES (HDAC2 AND SIRT1), DISRUPTION OF HDAC2/SIRT1-RELA/P65 COREPRESSOR COMPLEX ASSOCIATED WITH ACETYLATION OF RELA/P65, AND CHROMATIN MODIFICATIONS (HISTONE H3 PHOSPHO-ACETYLATION) LEADING TO SUSTAINED PRO-INFLAMMATORY GENE TRANSCRIPTION. KNOWLEDGE ON MOLECULAR MECHANISMS OF EPIGENETIC CHANGES IN ABNORMAL LUNG INFLAMMATION WILL HELP IN UNDERSTANDING THE PATHOPHYSIOLOGY OF COPD WHICH MAY LEAD TO THE DEVELOPMENT OF NOVEL EPIGENETIC THERAPIES IN THE NEAR FUTURE. 2009 14 6041 24 THE CLASS III HISTONE DEACETYLASE SIRTUIN 1 IN IMMUNE SUPPRESSION AND ITS THERAPEUTIC POTENTIAL IN RHEUMATOID ARTHRITIS. RHEUMATOID ARTHRITIS (RA) IS A CHRONIC DEBILITATING DISEASE OF THE JOINTS. BOTH THE INNATE AND ADAPTIVE IMMUNE RESPONSES PARTICIPATE IN THE DEVELOPMENT AND PROGRESSION OF RA. WHILE SEVERAL THERAPEUTIC REAGENTS, SUCH AS TNF-ALPHA AGONISTS, HAVE BEEN SUCCESSFULLY DEVELOPED FOR THE CLINICAL USE IN THE TREATMENT OF RA, MORE THAN HALF OF THE PATIENTS DO NOT RESPOND TO ANTI-TNF THERAPY. THEREFORE, NEW THERAPEUTIC REAGENTS ARE NEEDED. RECENT STUDIES HAVE SHOWN THAT SIRTUIN 1 (SIRT1), A NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD)-DEPENDENT HISTONE DEACETYLASE, IS A CRITICAL NEGATIVE REGULATOR OF BOTH THE INNATE AND ADAPTIVE IMMUNE RESPONSE IN MICE, AND ITS ALTERED FUNCTIONS ARE LIKELY TO BE INVOLVED IN AUTOIMMUNE DISEASES. SMALL MOLECULES THAT MODULATE SIRT1 FUNCTIONS ARE POTENTIAL THERAPEUTIC REAGENTS FOR AUTOIMMUNE INFLAMMATORY DISEASES. THIS REVIEW HIGHLIGHTS THE ROLE OF SIRT1 IN IMMUNE REGULATION AND RA. 2013 15 6103 32 THE EMERGING ROLE OF HDACS: PATHOLOGY AND THERAPEUTIC TARGETS IN DIABETES MELLITUS. DIABETES MELLITUS (DM) IS ONE OF THE PRINCIPAL MANIFESTATIONS OF METABOLIC SYNDROME AND ITS PREVALENCE WITH MODERN LIFESTYLE IS INCREASING INCESSANTLY. CHRONIC HYPERGLYCEMIA CAN INDUCE SEVERAL VASCULAR COMPLICATIONS THAT WERE REFERRED TO BE THE MAJOR CAUSE OF MORBIDITY AND MORTALITY IN DM. ALTHOUGH SEVERAL THERAPEUTIC TARGETS HAVE BEEN IDENTIFIED AND ACCESSED CLINICALLY, THE IMMINENT RISK OF DM AND ITS PREVALENCE ARE STILL ASCENDING. SUBSTANTIAL PIECES OF EVIDENCE REVEALED THAT HISTONE DEACETYLASE (HDAC) ISOFORMS CAN REGULATE VARIOUS MOLECULAR ACTIVITIES IN DM VIA EPIGENETIC AND POST-TRANSLATIONAL REGULATION OF SEVERAL TRANSCRIPTION FACTORS. TO DATE, 18 HDAC ISOFORMS HAVE BEEN IDENTIFIED IN MAMMALS THAT WERE CATEGORIZED INTO FOUR DIFFERENT CLASSES. CLASSES I, II, AND IV ARE REGARDED AS CLASSICAL HDACS, WHICH OPERATE THROUGH A ZN-BASED MECHANISM. IN CONTRAST, CLASS III HDACS OR SIRTUINS DEPEND ON NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD(+)) FOR THEIR MOLECULAR ACTIVITY. FUNCTIONALLY, MOST OF THE HDAC ISOFORMS CAN REGULATE BETA CELL FATE, INSULIN RELEASE, INSULIN EXPRESSION AND SIGNALING, AND GLUCOSE METABOLISM. MOREOVER, THE ROLES OF HDAC MEMBERS HAVE BEEN IMPLICATED IN THE REGULATION OF OXIDATIVE STRESS, INFLAMMATION, APOPTOSIS, FIBROSIS, AND OTHER PATHOLOGICAL EVENTS, WHICH SUBSTANTIALLY CONTRIBUTE TO DIABETES-RELATED VASCULAR DYSFUNCTIONS. THEREFORE, HDACS COULD SERVE AS THE POTENTIAL THERAPEUTIC TARGET IN DM TOWARDS DEVELOPING NOVEL INTERVENTION STRATEGIES. THIS REVIEW SHEDS LIGHT ON THE EMERGING ROLE OF HDACS/ISOFORMS IN DIABETIC PATHOPHYSIOLOGY AND EMPHASIZED THE SCOPE OF THEIR TARGETING IN DM FOR CONSTITUTING NOVEL INTERVENTIONAL STRATEGIES FOR METABOLIC DISORDERS/COMPLICATIONS. 2021 16 4598 19 NATURAL PRODUCTS: THE ROLE AND MECHANISM IN LOW-DENSITY LIPOPROTEIN OXIDATION AND ATHEROSCLEROSIS. ATHEROSCLEROSIS IS A CHRONIC INFLAMMATORY, METABOLIC, AND EPIGENETIC DISEASE, WHICH LEADS TO THE LIFE-THREATENING CORONARY ARTERY DISEASE. EMERGING STUDIES FROM BENCH TO BEDSIDE HAVE DEMONSTRATED THE PIVOTAL ROLE OF LOW-DENSITY LIPOPROTEIN (LDL) OXIDATION IN THE INITIATION AND PROGRESSION OF ATHEROSCLEROSIS. THIS ARTICLE HEREBY REVIEWS OXIDATION MECHANISM OF LDL, AND THE PRO-ATHEROGENIC AND BIOMARKER ROLE OF OXIDIZED LDL IN ATHEROSCLEROSIS. WE ALSO REVIEW THE PHARMACOLOGICAL EFFECTS OF SEVERAL REPRESENTATIVE NATURAL PRODUCTS (VITAMIN E, RESVERATROL, QUERCETIN, PROBUCOL, TANSHINONE IIA, EPIGALLOCATECHIN GALLATE, AND LYCOPENE) IN PROTECTING AGAINST LDL OXIDATION AND ATHEROSCLEROSIS. CLINICAL AND BASIC RESEARCH SUPPORTS THE BENEFICIAL EFFECTS OF THESE NATURAL PRODUCTS IN INHIBITING LDL OXIDATION AND PREVENTING ATHEROSCLEROSIS, BUT THE DATA ARE STILL CONTROVERSIAL. THIS MAY BE RELATED TO FACTORS SUCH AS THE POPULATION AND THE DOSAGE AND TIME OF TAKING NATURAL PRODUCTS INVOLVED IN DIFFERENT STUDIES. UNDERSTANDING THE MECHANISM OF LDL OXIDATION AND EFFECT OF OXIDIZED LDL HELP RESEARCHERS TO FIND NOVEL THERAPIES AGAINST ATHEROSCLEROSIS. 2021 17 3344 26 HISTONE DEACETYLASES (HDACS) AND ATHEROSCLEROSIS: A MECHANISTIC AND PHARMACOLOGICAL REVIEW. ATHEROSCLEROSIS (AS), THE MOST COMMON UNDERLYING PATHOLOGY FOR CORONARY ARTERY DISEASE, IS A CHRONIC INFLAMMATORY, PROLIFERATIVE DISEASE IN LARGE- AND MEDIUM-SIZED ARTERIES. THE VASCULAR ENDOTHELIUM IS IMPORTANT FOR MAINTAINING VASCULAR HEALTH. ENDOTHELIAL DYSFUNCTION IS A CRITICAL EARLY EVENT LEADING TO AS, WHICH IS A MAJOR RISK FACTOR FOR STROKE AND MYOCARDIAL INFARCTION. ACCUMULATING EVIDENCE HAS SUGGESTED THE CRITICAL ROLES OF HISTONE DEACETYLASES (HDACS) IN REGULATING VASCULAR CELL HOMEOSTASIS AND AS. THE PURPOSE OF THIS REVIEW IS TO PRESENT AN UPDATED VIEW ON THE ROLES OF HDACS (CLASS I, CLASS II, CLASS IV) AND HDAC INHIBITORS IN VASCULAR DYSFUNCTION AND AS. WE ALSO ELABORATE ON THE NOVEL THERAPEUTIC TARGETS AND AGENTS IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASES. 2020 18 296 19 AGING, CELL SENESCENCE, THE PATHOGENESIS AND TARGETED THERAPIES OF OSTEOARTHRITIS. OSTEOARTHRITIS (OA) IS A CHRONIC, DEBILITATING JOINT DISEASE CHARACTERIZED BY PROGRESSIVE DESTRUCTION OF ARTICULAR CARTILAGE. FOR A LONG TIME, OA HAS BEEN CONSIDERED AS A DEGENERATIVE DISEASE, WHILE RECENT OBSERVATIONS INDICATE THE MECHANISMS RESPONSIBLE FOR THE PATHOGENESIS OF OA ARE MULTIFACETED. AGING IS A KEY FACTOR IN ITS DEVELOPMENT. CURRENT TREATMENTS ARE PALLIATIVE AND NO DISEASE MODIFYING ANTI-OSTEOARTHRITIS DRUGS (DMOADS) ARE AVAILABLE. IN ADDITION TO ARTICULAR CARTILAGE DEGRADATION, CELLULAR SENESCENCE, SYNOVIAL INFLAMMATION, AND EPIGENETIC ALTERATIONS MAY ALL HAVE A ROLE IN ITS FORMATION. ACCUMULATING DATA DEMONSTRATE A CLEAR RELATIONSHIP BETWEEN THE SENESCENCE OF ARTICULAR CHONDROCYTES AND OA FORMATION AND PROGRESSION. INHIBITION OF CELL SENESCENCE MAY HELP IDENTIFY NEW AGENTS WITH THE PROPERTIES OF DMOADS. SEVERAL ANTI-CELLULAR SENESCENCE STRATEGIES HAVE BEEN PROPOSED AND THESE INCLUDE SIRTUIN-ACTIVATING COMPOUNDS (STACS), SENOLYTICS, AND SENOMORPHICS DRUGS. THESE AGENTS MAY SELECTIVELY REMOVE SENESCENT CELLS OR AMELIORATE THEIR HARMFUL EFFECTS. THE RESULTS FROM PRECLINICAL EXPERIMENTS AND CLINICAL TRIALS ARE INSPIRING. HOWEVER, MORE STUDIES ARE WARRANTED TO CONFIRM THEIR EFFICACY, SAFETY PROFILES AND ADVERSE EFFECTS OF THESE AGENTS. 2021 19 5560 27 ROLE OF HISTONE DEACETYLASE 2 IN EPIGENETICS AND CELLULAR SENESCENCE: IMPLICATIONS IN LUNG INFLAMMAGING AND COPD. HISTONE DEACETYLASE 2 (HDAC2) IS A CLASS I HISTONE DEACETYLASE THAT REGULATES VARIOUS CELLULAR PROCESSES, SUCH AS CELL CYCLE, SENESCENCE, PROLIFERATION, DIFFERENTIATION, DEVELOPMENT, APOPTOSIS, AND GLUCOCORTICOID FUNCTION IN INHIBITING INFLAMMATORY RESPONSE. HDAC2 HAS BEEN SHOWN TO PROTECT AGAINST DNA DAMAGE RESPONSE AND CELLULAR SENESCENCE/PREMATURE AGING VIA AN EPIGENETIC MECHANISM IN RESPONSE TO OXIDATIVE STRESS. THESE PHENOMENA ARE OBSERVED IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). HDAC2 IS POSTTRANSLATIONALLY MODIFIED BY OXIDATIVE/CARBONYL STRESS IMPOSED BY CIGARETTE SMOKE AND OXIDANTS, LEADING TO ITS REDUCTION VIA AN UBIQUITINATION-PROTEASOME DEPENDENT DEGRADATION IN LUNGS OF PATIENTS WITH COPD. IN THIS PERSPECTIVE, WE HAVE DISCUSSED THE ROLE OF HDAC2 POSTTRANSLATIONAL MODIFICATIONS AND ITS ROLE IN REGULATION OF INFLAMMATION, HISTONE/DNA EPIGENETIC MODIFICATIONS, DNA DAMAGE RESPONSE, AND CELLULAR SENESCENCE, PARTICULARLY IN INFLAMMAGING, AND DURING THE DEVELOPMENT OF COPD. WE HAVE ALSO DISCUSSED THE POTENTIAL DIRECTIONS FOR FUTURE TRANSLATIONAL RESEARCH AVENUES IN MODULATING LUNG INFLAMMAGING AND CELLULAR SENESCENCE BASED ON EPIGENETIC CHROMATIN MODIFICATIONS IN DISEASES ASSOCIATED WITH INCREASED OXIDATIVE STRESS. 2012 20 5410 25 REGULATION OF ADAPTIVE IMMUNE CELLS BY SIRTUINS. IT IS NOW WELL-ESTABLISHED THAT THE PATHWAYS THAT CONTROL LYMPHOCYTE METABOLISM AND FUNCTION ARE INTIMATELY LINKED, AND CHANGES IN LYMPHOCYTE METABOLISM CAN INFLUENCE AND DIRECT CELLULAR FUNCTION. INTERESTINGLY, A NUMBER OF RECENT ADVANCES INDICATE THAT LYMPHOCYTE IDENTITY AND METABOLISM IS PARTIALLY CONTROLLED VIA EPIGENETIC REGULATION. EPIGENETIC MECHANISMS, SUCH AS CHANGES IN DNA METHYLATION OR HISTONE ACETYLATION, HAVE BEEN FOUND TO ALTER IMMUNE FUNCTION AND PLAY A ROLE IN NUMEROUS CHRONIC DISEASE STATES. THERE ARE SEVERAL ENZYMES THAT CAN MEDIATE EPIGENETIC CHANGES; OF PARTICULAR INTEREST ARE SIRTUINS, PROTEIN DEACETYLASES THAT MEDIATE ADAPTIVE RESPONSES TO A VARIETY OF STRESSES (INCLUDING CALORIE RESTRICTION AND METABOLIC STRESS) AND ARE NOW UNDERSTOOD TO PLAY A SIGNIFICANT ROLE IN IMMUNITY. THIS REVIEW WILL FOCUS ON RECENT ADVANCES IN THE UNDERSTANDING OF HOW SIRTUINS AFFECT THE ADAPTIVE IMMUNE SYSTEM. THESE PATHWAYS ARE OF SIGNIFICANT INTEREST AS THERAPEUTIC TARGETS FOR THE TREATMENT OF AUTOIMMUNITY, CANCER, AND TRANSPLANT TOLERANCE. 2019